INDICATIONS AND LIMITATIONS OF USE
Vyvanse is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adult and pediatric patients 6 and older, and for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults. Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.